40
Participants
Start Date
August 7, 2019
Primary Completion Date
November 8, 2021
Study Completion Date
September 18, 2023
Fazisiran Injection
solution for subcutaneous (sc) injection
Placebo
sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
Columbia University Medical Center, New York
Fondazione IRCCS Policlinico S. Matteo, Pavia
Medical University of South Carolina (MUSC), Charleston
University of Florida Hepatology Research at CTRB, Gainesville
University of Alabama at Birmingham Medical Center, Birmingham
Vanderbilt University Medical Center, Nashville
Indiana University Health University Hospital, Indianapolis
Universitatsklinikum Aachen, Anstalt des offentlich, Aachen
University of Iowa Hospitals and Clinics, Iowa City
SSM-Health Cardinal Glennon Children's Hospital, St Louis
Baylor College of Medicine, Houston
University of Utah Hospital, Salt Lake City
Mayo Clinic Arizona, Phoenix
UCLA David Geffen School of Medicine, Center for Health Sciences, Los Angeles
University of California San Diego Altman Clinical and Translational Research Institute, La Jolla
UCSF Medical Center Benioff Children's Hospital, San Francisco
Stanford Health Care, Stanford
University of California Davis Medical Center, Sacramento
Leiden University Medical Center, Leiden
Hospital Central Do Funchal (Hospital Nelio Mendoca), Funchal
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Arrowhead Pharmaceuticals
INDUSTRY